North American Molecular Diagnostics (MDx) Market Report 2021-2031
Forecasts by Technology (Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), by Application (Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Diseases, Microbiology, Others), by Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (USA, Canada) PLUS Analysis of Leading MDx Companies AND COVID-19 Recovery Scenarios
Growing Prevalence of Infectious Diseases Anticipated to Augur Market Growth According to the CDC, in the U.S., hospital-acquired infections (HAI) account for over 1.5 million infections & nearly 95,000 associated deaths per year. Molecular diagnostic is critical in the field of infectious disease testing as it provides rapid & successful results. The rising prevalence of infectious diseases & hospital-acquired infections is therefore expected to fuel molecular diagnostics market across the North American region from 2021 to 2031.
Which Factors are Fueling North America Molecular Diagnostics Market Growth? – Growing Geriatric Population Base – Increase in Demand for Point-of-Care Facilities – Growing Prevalence of Target Diseases Such as Genetic, CVDs, and Neurological Diseases – Introduction of Technologically Advanced Products
Which Factors are Restraining Growth? – High Prices of Molecular Diagnostics Tests – Presence of Ambiguous Regulatory Framework to Impede Market Growth
Technological Advancements to Boost Market Growth According to Visiongain analysis, advancements in technology is projected to boost North American molecular diagnostics industry growth as they provide greater accuracy and are cost-effective. The market is likely to be guided by the launch of MinION, an affordable and compact sequencer that supplies users in small peripheral laboratories and point of care facilities. Also, high demand for over-the-counter diagnostics is expected to help drive market growth in this area. Furthermore, some of the key factors such as advanced cancer diagnostic testing coupled with growing demand for genetic testing is expected to fuel market growth further through 2031.
UNIQUE COVID-19 VARIATIONS– only available in this Visiongain report are dedicated analysis of 4 different rebound scenarios of how the market will develop – no matter how COVID-19 affects the economy.
How do prominent players strengthen their position throughout the world? You must read this newly updated report if you are involved in this sector. The report from Visiongain shows you potential revenues up to 2031, evaluate information, trends, opportunities and business outlooks.
Discover how to stay ahead Our 350+ page report provides 500+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall North American market and country level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing North America Molecular Diagnostics Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), SWOT Analysis, PEST Analysis, Porter’s Analysis, product profiles and commercial developments.
Discover sales predictions for the North American market and submarkets
Technology • Polymerase Chain Reaction – Multiplex PCR – Other PCR • In Situ Hybridization • Isothermal Nucleic Acid Amplification Technology • Chips and Microarrays • Mass Spectrometry • Sequencing • Transcription Mediated Amplification • Others
Application • Oncology – Breast Cancer – Prostate Cancer – Colorectal Cancer – Cervical Cancer – Kidney Cancer – Liver Cancer – Blood Cancer – Lung Cancer – Other Cancer • Pharmacogenomics • Infectious Diseases – Methicillin-Resistant Staphylococcus Aureus – Clostridium Difficile – Vancomycin-Resistant Enterococci – Carbapenem-Resistant Bacteria – Flu – Respiratory Syncytial Virus – Candida – Tuberculosis and Drug-Resistant TBA – Meningitis – Gastrointestinal Panel Testing – Chlamydia – Gonorrhea – HIV – Hepatitis C – Hepatitis B – Other Infectious Diseases • Genetic Testing – Newborn Screening – Predictive and Presymptomatic Testing – Other Genetic Testing • Neurological Disease • Cardiovascular Diseases • Microbiology • Others
Product • Instruments • Reagents
Test Location • Point-of-Care • Over the Counter • Central Laboratories
In addition to the revenue predictions for the overall North American market and segments, you will also find revenue forecasts for country by segments as well:
• U.S. Molecular Diagnostics Market – Revenue Forecasts by Technology – Revenue Forecasts by Application – Revenue Forecasts by Product – Revenue Forecasts by Test Location
• Canada Molecular Diagnostics Market – Revenue Forecasts by Technology – Revenue Forecasts by Application – Revenue Forecasts by Product – Revenue Forecasts by Test Location
Leading companies and the potential for market growth Overall revenue for North America molecular diagnostics market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Prospects for established firms and those seeking to enter the market– including company profiles for 16 of the major companies involved in the North America Molecular Diagnostics Market. Some of the companies profiled in this report include are Roche Diagnostics, Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bio-Rad Laboratories, Inc., Dako (Agilent Technologies), Danaher, FOUNDATION MEDICINE, INC., Genomic Health (Exact Sciences Corporation), Hologic, Inc., Illumina, Inc., HTG Molecular Diagnostics, Inc., Grifols, S.A., QIAGEN, Siemens Healthcare GmbH, and Sysmex Corporation.
Key Questions Answered by this Report: • What is the current size of the North America Molecular Diagnostics market? How much will this market be worth from 2021 to 2031? • What are the main drivers and restraints that will shape the North America Molecular Diagnostics market over the next ten years? • What are the main segments within the North America Molecular Diagnostics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why? • What factors will affect that industry and market over the next ten years? • What are the largest national markets for the North America Molecular Diagnostics? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2031? • How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031? • Which are the leading companies and what are their activities, results, developments, and prospects? • What are the main trends that will affect the North America Molecular Diagnostics market between 2021 and 2031? • What are the main strengths, weaknesses, opportunities, and threats for the market? • How will the North America Molecular Diagnostics market evolve over the forecasted period, 2021 to 2031? • How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is intended for everybody needing commercial analyses for the North America Molecular Diagnostics Market and leading companies. You will find data, trends and predictions.
Buy our report today North American Molecular Diagnostics (MDx) Market Report 2021-2031: Forecasts by Technology (Polymerase Chain Reaction, In Situ Hybridization, Isothermal Nucleic Acid Amplification Technology, Chips and Microarrays, Mass Spectrometry, Sequencing, Transcription Mediated Amplification, Others), by Application (Oncology, Pharmacogenomics, Infectious Diseases, Genetic Testing, Neurological Disease, Cardiovascular Diseases, Microbiology, Others), by Product (Instruments, Reagents), Test Location (Point-of-Care, Over the Counter, Central Laboratories), by Country (USA, Canada) PLUS Analysis of Leading MDx Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview 1.1 Introduction to Molecular Diagnostics Market 1.2 Molecular Diagnostics Market Definition 1.3 Why You Should Read This Report 1.4 What This Report Delivers 1.5 Key Questions Answered By This Analytical Report Include: 1.6 Who is This Report For? 1.7 Methodology 1.7.1 COVID-19 Impact: Recovery Scenarios 1.7.2 Market Evaluation & Forecasting Methodology 1.8 Frequently Asked Questions (FAQs) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2 Executive Summary
3 Market Dynamics 3.1 Drivers 3.1.1 Growing Geriatric Population Base 3.1.2 Increase in Demand for Point-of-Care Facilities 3.1.3 Growing Prevalence of Target Diseases Such as Genetic, CVDs, Neurological Diseases etc. 3.2 Restraints 3.2.1 High Prices of Molecular Diagnostics Tests 3.2.2 Presence of Ambiguous Regulatory Framework to Impede Market Growth 3.3 Opportunities 3.3.1 Technological Advancements to Pave Way for Fresh Revenue Pockets 3.3.2 Growing Demand from Emerging Economies to Offer Lucrative Growth Opportunities 3.3.3 Increase in the Adoption of Automation and Multiplexing of Technologies 3.4 SWOT Analysis 3.4.1 Strengths 3.4.2 Weaknesses 3.4.3 Opportunities 3.4.4 Threats 3.5 Industry analysis - Porter’s 3.5.1 Buyer Power 3.5.2 Supplier Power 3.5.3 Competitive Rivalry 3.5.4 Threat of Substitute 3.5.5 Threat of New Entrants 3.6 Industry analysis – PEST Analysis 3.6.1 Political Factors Impacting Molecular Diagnostics Market 3.6.2 Economic Factors Impacting Molecular Diagnostics Market 3.6.3 Social Factors Impacting Molecular Diagnostics Market 3.6.4 Technological Factors Impacting Molecular Diagnostics Market
4 North America Molecular Diagnostics Market by Technology 4.1 Polymerase Chain Reaction Segment Market Forecast, 2021-2031 4.1.1 Technological Advancements to Fuel PCR Segment Growth 4.1.2 Polymerase Chain Reaction Market by Sub-Segment, 2021-2031 4.1.3 Recovery Scenarios (V, U, W, L) 4.2 In Situ Hybridization Segment Market Forecast, 2021-2031 4.2.1 Increasing Incidence of Genetic Disorder and Cancer to Boost ISH Market Growth 4.2.2 Recovery Scenarios (V, U, W, L) 4.3 Isothermal Nucleic Acid Amplification Technology Segment Market Forecast, 2021-2031 4.3.1 Rising Prevalence of Infectious Disease to Drive INAAT Market Growth 4.3.2 Recovery Scenarios (V, U, W, L) 4.4 Chips and Microarrays Segment Market Forecast, 2021-2031 4.4.1 Increasing Usage in Basic Molecular Biology to Drive Segmental Growth 4.4.2 Recovery Scenarios (V, U, W, L) 4.5 Mass Spectrometry Segment Market Forecast, 2021-2031 4.5.1 Multidimensional Analysis and Evaluation of Impurities During Drug Development Process Fuelling Market Growth 4.5.2 Recovery Scenarios (V, U, W, L) 4.6 Sequencing Segment Market Forecast, 2021-2031 4.6.1 Sequencing Segment to Offer Massive Advances in Diagnosis, Prognosis and Treatment of Disease 4.6.2 Recovery Scenarios (V, U, W, L) 4.7 Transcription Mediated Amplification Segment Market Forecast, 2021-2031 4.7.1 Recovery Scenarios (V, U, W, L) 4.8 Others Segment Market Forecast, 2021-2031 4.8.1 Recovery Scenarios (V, U, W, L)
5 North America Molecular Diagnostics Market by Application 5.1 Oncology Segment Market Forecast, 2021-2031 5.1.1 Rising Prevalence of Cancer to Propel Market Growth 5.1.2 Oncology Market by Sub-Segment, 2021-2031 5.1.3 Recovery Scenarios (V, U, W, L) 5.2 Pharmacogenomics Segment Market Forecast, 2021-2031 5.2.1 Increasing Importance Across Emerging Economies to Fuel Pharmacogenomics Market Growth 5.2.2 Recovery Scenarios (V, U, W, L) 5.3 Infectious Diseases Segment Market Forecast, 2021-2031 5.3.1 Technological Advancements to Propel Usage of Molecular Diagnostics for Infectious Diseases 5.3.2 Infectious Diseases Market by Sub-Segment, 2021-2031 5.3.3 Recovery Scenarios (V, U, W, L) 5.4 Genetic Testing Segment Market Forecast, 2021-2031 5.4.1 Genetic Testing Has Led to Expansion of Molecular Techniques Withing Clinical Laboratories 5.4.2 Genetic Testing Market by Sub-Segment, 2021-2031 5.4.3 Recovery Scenarios (V, U, W, L) 5.5 Neurological Disease Segment Market Forecast, 2021-2031 5.5.1 Molecular Diagnostics for Infectious Diseases to Witness Significant Growth 5.5.2 Recovery Scenarios (V, U, W, L) 5.6 Cardiovascular Diseases Segment Market Forecast, 2021-2031 5.6.1 Growing Burden of CVDs Across Emerging Economies to Fuel Segmental Market Growth 5.6.2 Recovery Scenarios (V, U, W, L) 5.7 Microbiology Segment Market Forecast, 2021-2031 5.7.1 Technological Advancements Fuelling Microbiology Segment Growth 5.7.2 Recovery Scenarios (V, U, W, L) 5.8 Others Segment Market Forecast, 2021-2031 5.8.1 Recovery Scenarios (V, U, W, L)
6 North America Molecular Diagnostics Market by Product 6.1 Instruments Segment Market Forecast, 2021-2031 6.1.1 Strong Demand from Emerging Economies for Advanced Instruments 6.1.2 Recovery Scenarios (V, U, W, L) 6.2 Reagents Segment Market Forecast, 2021-2031 6.2.1 Reagents Segment Accounts for Majority of the Market Share 6.2.2 Recovery Scenarios (V, U, W, L)
7 North America Molecular Diagnostics Market by Test Location 7.1 Point-of-Care Segment Market Forecast, 2021-2031 7.1.1 Recovery Scenarios (V, U, W, L) 7.2 Over the Counter Segment Market Forecast, 2021-2031 7.2.1 Recovery Scenarios (V, U, W, L) 7.3 Central Laboratories Segment Market Forecast, 2021-2031 7.3.1 Recovery Scenarios (V, U, W, L)
8 North America Molecular Diagnostics Market by Country 8.1 Largest Molecular Diagnostics Market Globally 8.2 North America Molecular Diagnostics Market by Country, Forecast 2021-2031 8.3 U.S. Molecular Diagnostics Market Forecast by Technology 8.3.1 Recovery Scenarios (V, U, W, L) 8.4 U.S. Molecular Diagnostics Market Forecast by Application 8.4.1 Recovery Scenarios (V, U, W, L) 8.5 U.S. Molecular Diagnostics Market Forecast by Product 8.5.1 Recovery Scenarios (V, U, W, L) 8.6 U.S. Molecular Diagnostics Market Forecast by Test Location 8.6.1 Recovery Scenarios (V, U, W, L) 8.7 U.S. Molecular Diagnostics Market Forecast, 2021-2031 8.7.1 U.S. Accounts for Majority of the North American Molecular Diagnostics Market 8.7.2 Recovery Scenarios (V, U, W, L): U.S. Molecular Diagnostics Market Forecast, 2021-2031 8.8 Canada Molecular Diagnostics Market Forecast by Technology 8.8.1 Recovery Scenarios (V, U, W, L) 8.9 Canada Molecular Diagnostics Market Forecast by Application 8.9.1 Recovery Scenarios (V, U, W, L) 8.10 Canada Molecular Diagnostics Market Forecast by Product 8.10.1 Recovery Scenarios (V, U, W, L) 8.11 Canada Molecular Diagnostics Market Forecast by Test Location 8.11.1 Recovery Scenarios (V, U, W, L) 8.12 Canada Molecular Diagnostics Market Forecast, 2021-2031 8.12.1 Rising Investments by Government to Spur Regional Market Growth 8.12.2 Recovery Scenarios (V, U, W, L): Canada Molecular Diagnostics Market Forecast, 2021-2031
9 Company Profiles 9.1 Roche Diagnostics 9.1.1 Company Snapshot 9.1.2 Company Overview 9.1.3 Financial Analysis 9.1.3.1 Net Revenue, 2015-2019 9.1.3.2 R&D Expenses, 2015-2019 9.1.3.3 Gross Profit, 2015-2019 9.1.3.4 Net Income, 2015-2019 9.1.3.5 EBDITA, 2015-2019 9.1.4 Product Benchmarking 9.1.5 Recent Developments, 2017-2020 9.2 Abbott 9.2.1 Company Snapshot 9.2.2 Company Overview 9.2.3 Financial Analysis 9.2.3.1 Net Revenue, 2015-2019 9.2.3.2 R&D Expenses, 2015-2019 9.2.3.3 Gross Profit, 2015-2019 9.2.3.4 Net Income, 2015-2019 9.2.3.5 EBDITA, 2015-2019 9.2.4 Product Benchmarking 9.3 Becton, Dickinson and Company 9.3.1 Company Snapshot 9.3.2 Company Overview 9.3.3 Financial Analysis 9.3.3.1 Net Revenue, 2015-2020 9.3.3.2 R&D Expenses, 2015-2020 9.3.3.3 Gross Profit, 2015-2020 9.3.3.4 Net Income, 2015-2020 9.3.3.5 EBDITA, 2015-2020 9.3.4 Product Benchmarking 9.3.5 Recent Developments, 2017-2020 9.4 bioMérieux SA 9.4.1 Company Snapshot 9.4.2 Company Overview 9.4.3 Financial Analysis 9.4.3.1 Net Revenue, 2016-2019 9.4.3.2 R&D Expenses, 2015-2019 9.4.3.3 Gross Profit, 2015-2019 9.4.3.4 Net Income, 2016-2019 9.4.3.5 EBDITA, 2015-2019 9.4.4 Product Benchmarking 9.4.5 Recent Developments, 2017-2020 9.5 Bio-Rad Laboratories, Inc. 9.5.1 Company Snapshot 9.5.2 Company Overview 9.5.3 Financial Analysis 9.5.3.1 Net Revenue, 2015-2019 9.5.3.2 R&D Expenses, 2015-2019 9.5.3.3 Gross Profit, 2015-2019 9.5.3.4 Net Income, 2015-2019 9.5.3.5 EBDITA, 2015-2019 9.5.4 Product Benchmarking 9.5.5 Recent Developments, 2017-2020 9.6 Dako (Agilent Technologies) 9.6.1 Company Snapshot 9.6.2 Company Overview 9.6.3 Financial Analysis 9.6.3.1 Net Revenue, 2015-2020 9.6.3.2 R&D Expenses, 2015-2020 9.6.3.3 Gross Profit, 2015-2020 9.6.3.4 Net Income, 2015-2020 9.6.3.5 EBDITA, 2015-2020 9.6.4 Product Benchmarking 9.6.5 Recent Developments, 2017-2020 9.7 Danaher 9.7.1 Company Snapshot 9.7.2 Company Overview 9.7.3 Financial Analysis 9.7.3.1 Net Revenue, 2015-2019 9.7.3.2 R&D Expenses, 2015-2019 9.7.3.3 Gross Profit, 2015-2019 9.7.3.4 Net Income, 2015-2019 9.7.3.5 EBDITA, 2015-2019 9.7.4 Product Benchmarking 9.8 FOUNDATION MEDICINE, INC. 9.8.1 Company Snapshot 9.8.2 Company Overview 9.8.3 Product Benchmarking 9.8.4 Recent Developments, 2017-2020 9.9 Genomic Health (Exact Sciences Corporation) 9.9.1 Company Snapshot 9.9.2 Company Overview 9.9.3 Financial Analysis 9.9.3.1 Net Revenue, 2015-2019 9.9.3.2 R&D Expenses, 2015-2019 9.9.3.3 Gross Profit, 2015-2019 9.9.3.4 Net Income, 2015-2019 9.9.3.5 EBDITA, 2015-2019 9.9.4 Product Benchmarking 9.9.5 Recent Developments, 2017-2020 9.10 Hologic, Inc. 9.10.1 Company Snapshot 9.10.2 Company Overview 9.10.3 Financial Analysis 9.10.3.1 Net Revenue, 2015-2020 9.10.3.2 R&D Expenses, 2015-2020 9.10.3.3 Gross Profit, 2015-2020 9.10.3.4 Net Income, 2015-2020 9.10.3.5 EBDITA, 2015-2020 9.10.4 Product Benchmarking 9.10.5 Recent Developments, 2017-2020 9.11 Illumina, Inc. 9.11.1 Company Snapshot 9.11.2 Company Overview 9.11.3 Financial Analysis 9.11.3.1 Net Revenue, 2015-2019 9.11.3.2 R&D Expenses, 2015-2019 9.11.3.3 Gross Profit, 2015-2019 9.11.3.4 Net Income, 2015-2019 9.11.3.5 EBDITA, 2015-2019 9.11.4 Product Benchmarking 9.11.5 Recent Developments, 2017-2020 9.12 HTG Molecular Diagnostics, Inc. 9.12.1 Company Snapshot 9.12.2 Company Overview 9.12.3 Financial Analysis 9.12.3.1 Net Revenue, 2015-2019 9.12.3.2 R&D Expenses, 2015-2019 9.12.3.3 Gross Profit, 2015-2019 9.12.3.4 Net Income, 2015-2019 9.12.3.5 EBDITA, 2015-2019 9.12.4 Product Benchmarking 9.12.5 Recent Developments, 2017-2020 9.13 Grifols, S.A. 9.13.1 Company Snapshot 9.13.2 Company Overview 9.13.3 Financial Analysis 9.13.3.1 Net Revenue, 2015-2019 9.13.3.2 R&D Expenses, 2015-2019 9.13.3.3 Gross Profit, 2015-2019 9.13.3.4 Net Income, 2015-2019 9.13.3.5 EBDITA, 2015-2019 9.13.4 Product Benchmarking 9.13.5 Recent Developments, 2017-2020 9.14 QIAGEN 9.14.1 Company Snapshot 9.14.2 Company Overview 9.14.3 Financial Analysis 9.14.3.1 Net Revenue, 2015-2019 9.14.3.2 R&D Expenses, 2015-2019 9.14.3.3 Gross Profit, 2015-2019 9.14.3.4 Net Income, 2015-2019 9.14.3.5 EBDITA, 2015-2019 9.14.4 Product Benchmarking 9.14.5 Recent Developments, 2017-2020 9.15 Siemens Healthcare GmbH 9.15.1 Company Snapshot 9.15.2 Company Overview 9.15.3 Financial Analysis 9.15.3.1 Net Revenue, 2015-2020 9.15.3.2 R&D Expenses, 2015-2020 9.15.3.3 Gross Profit, 2015-2020 9.15.3.4 Net Income, 2015-2020 9.15.3.5 EBDITA, 2015-2020 9.15.4 Product Benchmarking 9.16 Sysmex Corporation 9.16.1 Company Snapshot 9.16.2 Company Overview 9.16.3 Financial Analysis 9.16.3.1 Net Revenue, 2016-2020 9.16.3.2 Gross Profit, 2016-2020 9.16.3.3 Net Income, 2016-2020 9.16.3.4 EBDITA, 2016-2020 9.16.4 Product Benchmarking 9.16.5 Recent Developments, 2017-2020
10 Conclusion and Recommendations 10.1 Concluding Remarks 10.2 Recommendations
List of Tables Table 1 Global Molecular Diagnostics Market Snapshot, 2020 & 2030 (US$ million, CAGR %) Table 2 North America Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ mn, AGR%, CAGR%) Table 3 North America Molecular Diagnostics Market Forecast for Polymerase Chain Reaction Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 4 North America Molecular Diagnostics Market Forecast by PCR, 2021-2031 (US$ mn, AGR%, CAGR%) Table 5 North America Molecular Diagnostics Market Forecast for Polymerase Chain Reaction Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 6 North America Molecular Diagnostics Market Forecast for Polymerase Chain Reaction Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 7 North America Molecular Diagnostics Market Forecast for Polymerase Chain Reaction Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 8 North America Molecular Diagnostics Market Forecast for Polymerase Chain Reaction Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 9 North America Molecular Diagnostics Market Forecast for In Situ Hybridization Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 10 North America Molecular Diagnostics Market Forecast for In Situ Hybridization Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 11 North America Molecular Diagnostics Market Forecast for In Situ Hybridization Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 12 North America Molecular Diagnostics Market Forecast for In Situ Hybridization Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 13 North America Molecular Diagnostics Market Forecast for In Situ Hybridization Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 14 North America Molecular Diagnostics Market Forecast for Isothermal Nucleic Acid Amplification Technology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 15 North America Molecular Diagnostics Market Forecast for Isothermal Nucleic Acid Amplification Technology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 16 North America Molecular Diagnostics Market Forecast for Isothermal Nucleic Acid Amplification Technology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 17 North America Molecular Diagnostics Market Forecast for Isothermal Nucleic Acid Amplification Technology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 18 North America Molecular Diagnostics Market Forecast for Isothermal Nucleic Acid Amplification Technology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 19 North America Molecular Diagnostics Market Forecast for Chips and Microarrays Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 20 North America Molecular Diagnostics Market Forecast for Chips and Microarrays Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 21 North America Molecular Diagnostics Market Forecast for Chips and Microarrays Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 22 North America Molecular Diagnostics Market Forecast for Chips and Microarrays Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 23 North America Molecular Diagnostics Market Forecast for Chips and Microarrays Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 24 North America Molecular Diagnostics Market Forecast for Mass Spectrometry Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 25 North America Molecular Diagnostics Market Forecast for Mass Spectrometry Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 26 North America Molecular Diagnostics Market Forecast for Mass Spectrometry Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 27 North America Molecular Diagnostics Market Forecast for Mass Spectrometry Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 28 North America Molecular Diagnostics Market Forecast for Mass Spectrometry Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 29 North America Molecular Diagnostics Market Forecast for Sequencing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 30 North America Molecular Diagnostics Market Forecast for Sequencing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 31 North America Molecular Diagnostics Market Forecast for Sequencing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 32 North America Molecular Diagnostics Market Forecast for Sequencing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 33 North America Molecular Diagnostics Market Forecast for Sequencing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 34 North America Molecular Diagnostics Market Forecast for Transcription Mediated Amplification Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 35 North America Molecular Diagnostics Market Forecast for Transcription Mediated Amplification Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 36 North America Molecular Diagnostics Market Forecast for Transcription Mediated Amplification Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 37 North America Molecular Diagnostics Market Forecast for Transcription Mediated Amplification Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 38 North America Molecular Diagnostics Market Forecast for Transcription Mediated Amplification Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 39 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 40 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 41 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 42 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 43 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 44 North America Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ mn, AGR%, CAGR%) Table 45 North America Molecular Diagnostics Market Forecast for Oncology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 46 North America Molecular Diagnostics Market Forecast by Oncology, 2021-2031 (US$ mn, AGR%, CAGR%) Table 47 North America Molecular Diagnostics Market Forecast for Oncology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 48 North America Molecular Diagnostics Market Forecast for Oncology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 49 North America Molecular Diagnostics Market Forecast for Oncology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 50 North America Molecular Diagnostics Market Forecast for Oncology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 51 North America Molecular Diagnostics Market Forecast for Pharmacogenomics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 52 North America Molecular Diagnostics Market Forecast for Pharmacogenomics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 53 North America Molecular Diagnostics Market Forecast for Pharmacogenomics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 54 North America Molecular Diagnostics Market Forecast for Pharmacogenomics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 55 North America Molecular Diagnostics Market Forecast for Pharmacogenomics Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 56 North America Molecular Diagnostics Market Forecast for Infectious Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 57 North America Molecular Diagnostics Market Forecast by Infectious Diseases, 2021-2031 (US$ mn, AGR%, CAGR%) Table 58 North America Molecular Diagnostics Market Forecast for Infectious Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 59 North America Molecular Diagnostics Market Forecast for Infectious Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 60 North America Molecular Diagnostics Market Forecast for Infectious Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 61 North America Molecular Diagnostics Market Forecast for Infectious Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 62 North America Molecular Diagnostics Market Forecast for Genetic Testing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 63 North America Molecular Diagnostics Market Forecast by Genetic Testing 2021-2031 (US$ mn, AGR%, CAGR%) Table 64 North America Molecular Diagnostics Market Forecast for Genetic Testing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 65 North America Molecular Diagnostics Market Forecast for Genetic Testing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 66 North America Molecular Diagnostics Market Forecast for Genetic Testing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 67 North America Molecular Diagnostics Market Forecast for Genetic Testing Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 68 North America Molecular Diagnostics Market Forecast for Neurological Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 69 North America Molecular Diagnostics Market Forecast for Neurological Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 70 North America Molecular Diagnostics Market Forecast for Neurological Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 71 North America Molecular Diagnostics Market Forecast for Neurological Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 72 North America Molecular Diagnostics Market Forecast for Neurological Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 73 North America Molecular Diagnostics Market Forecast for Cardiovascular Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 74 North America Molecular Diagnostics Market Forecast for Cardiovascular Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 75 North America Molecular Diagnostics Market Forecast for Cardiovascular Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 76 North America Molecular Diagnostics Market Forecast for Cardiovascular Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 77 North America Molecular Diagnostics Market Forecast for Cardiovascular Diseases Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 78 North America Molecular Diagnostics Market Forecast for Microbiology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 79 North America Molecular Diagnostics Market Forecast for Microbiology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 80 North America Molecular Diagnostics Market Forecast for Microbiology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 81 North America Molecular Diagnostics Market Forecast for Microbiology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 82 North America Molecular Diagnostics Market Forecast for Microbiology Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 83 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 84 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 85 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 86 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 87 North America Molecular Diagnostics Market Forecast for Others Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 88 North America Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ mn, AGR%, CAGR%) Table 89 North America Molecular Diagnostics Market Forecast for Instruments Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 90 North America Molecular Diagnostics Market Forecast for Instruments Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 91 North America Molecular Diagnostics Market Forecast for Instruments Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 92 North America Molecular Diagnostics Market Forecast for Instruments Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 93 North America Molecular Diagnostics Market Forecast for Instruments Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 94 North America Molecular Diagnostics Market Forecast for Reagents Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 95 North America Molecular Diagnostics Market Forecast for Reagents Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 96 North America Molecular Diagnostics Market Forecast for Reagents Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 97 North America Molecular Diagnostics Market Forecast for Reagents Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 98 North America Molecular Diagnostics Market Forecast for Reagents Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 99 North America Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ mn, AGR%, CAGR%) Table 100 North America Molecular Diagnostics Market Forecast for Point of Care Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 101 North America Molecular Diagnostics Market Forecast for Point of Care Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 102 North America Molecular Diagnostics Market Forecast for Point of Care Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 103 North America Molecular Diagnostics Market Forecast for Point of Care Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 104 North America Molecular Diagnostics Market Forecast for Point of Care Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 105 North America Molecular Diagnostics Market Forecast for Over the Counter Segment, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 106 North America Molecular Diagnostics Market Forecast for Over the Counter Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 107 North America Molecular Diagnostics Market Forecast for Over the Counter Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 108 North America Molecular Diagnostics Market Forecast for Over the Counter Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 109 North America Molecular Diagnostics Market Forecast for Over the Counter Segment, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 110 North America Molecular Diagnostics Market Forecast for Central Laboratories, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 111 North America Molecular Diagnostics Market Forecast for Central Laboratories, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 112 North America Molecular Diagnostics Market Forecast for Central Laboratories, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 113 North America Molecular Diagnostics Market Forecast for Central Laboratories, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 114 North America Molecular Diagnostics Market Forecast for Central Laboratories, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 115 North America Molecular Diagnostics Market Forecast by country 2021-2031 (US$ mn, AGR%, CAGR%) Table 116 U.S. Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ mn, AGR%, CAGR%) Table 117 U.S. Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 118 U.S. Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 119 U.S. Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 120 U.S. Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 121 U.S. Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ mn, AGR%, CAGR%) Table 122 U.S. Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 123 U.S. Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 124 U.S. Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 125 U.S. Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 126 U.S. Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ mn, AGR%, CAGR%) Table 127 U.S. Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 128 U.S. Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 129 U.S. Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 130 U.S. Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 131 U.S. Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ mn, AGR%, CAGR%) Table 132 U.S. Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 133 U.S. Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 134 U.S. Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 135 U.S. Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 136 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 137 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 138 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 139 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 140 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 141 Canada Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ mn, AGR%, CAGR%) Table 142 Canada Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 143 Canada Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 144 Canada Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 145 Canada Molecular Diagnostics Market Forecast by Technology 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 146 Canada Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ mn, AGR%, CAGR%) Table 147 Canada Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 148 Canada Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 149 Canada Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 150 Canada Molecular Diagnostics Market Forecast by Application 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 151 Canada Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ mn, AGR%, CAGR%) Table 152 Canada Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 153 Canada Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 154 Canada Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 155 Canada Molecular Diagnostics Market Forecast by Product 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 156 Canada Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ mn, AGR%, CAGR%) Table 157 Canada Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 158 Canada Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 159 Canada Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 160 Canada Molecular Diagnostics Market Forecast by Test Location 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 161 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%) Table 162 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "V" Shaped Recovery Table 163 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "U" Shaped Recovery Table 164 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "W" Shaped Recovery Table 165 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ Mn, AGR%, CAGR%): "L" Shaped Recovery Table 166 Roche Diagnostics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 167 Roche Diagnostics: Product Benchmarking Table 168 Roche Diagnostics: Recent Developments, 2017-2020 Table 169 Abbott: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 170 Abbott: Product Benchmarking Table 171 Abbott: Recent Developments, 2017-2020 Table 172 Becton, Dickinson and Company: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 173 Becton, Dickinson and Company: Product Benchmarking Table 174 Becton, Dickinson and Company: Recent Developments, 2017-2020 Table 175 bioMérieux SA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 176 bioMérieux SA: Product Benchmarking Table 177 bioMérieux SA: Recent Developments, 2017-2020 Table 178 Bio-Rad Laboratories, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 179 Bio-Rad Laboratories, Inc.: Product Benchmarking Table 180 Bio-Rad Laboratories, Inc.: Recent Developments, 2017-2020 Table 181 Dako (Agilent Technologies): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 182 Dako (Agilent Technologies): Product Benchmarking Table 183 Dako (Agilent Technologies): Recent Developments, 2017-2020 Table 184 Danaher: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 185 Danaher: Product Benchmarking Table 186 Danaher: Recent Developments, 2017-2020 Table 187 FOUNDATION MEDICINE, INC.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 188 FOUNDATION MEDICINE, INC.: Product Benchmarking Table 189 FOUNDATION MEDICINE, INC.: Recent Developments, 2017-2020 Table 190 Genomic Health (Exact Sciences Corporation): Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 191 Genomic Health (Exact Sciences Corporation): Product Benchmarking Table 192 Genomic Health (Exact Sciences Corporation): Recent Developments, 2017-2020 Table 193 Hologic, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 194 Hologic, Inc.: Product Benchmarking Table 195 Hologic, Inc.: Recent Developments, 2017-2020 Table 196 Illumina, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 197 Illumina, Inc.: Product Benchmarking Table 198 Illumina, Inc.: Recent Developments, 2017-2020 Table 199 HTG Molecular Diagnostics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 200 HTG Molecular Diagnostics, Inc.: Product Benchmarking Table 201 HTG Molecular Diagnostics, Inc.: Recent Developments, 2017-2020 Table 202 Grifols, S.A.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 203 Grifols, S.A.: Product Benchmarking Table 204 Grifols, S.A.: Recent Developments, 2017-2020 Table 205 QIAGEN: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 206 QIAGEN: Product Benchmarking Table 207 QIAGEN: Recent Developments, 2017-2020 Table 208 Siemens Healthcare GmbH: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 209 Siemens Healthcare GmbH: Product Benchmarking Table 210 Siemens Healthcare GmbH: Recent Developments, 2017-2020 Table 211 Sysmex Corporation: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment) Table 212 Sysmex Corporation: Product Benchmarking Table 213 Sysmex Corporation: Recent Developments, 2017-2020
List of Figures Figure 1 Global Molecular Diagnostics Market: Market Segmentation Figure 2 North America Molecular Diagnostics Market: Market Dynamics Figure 3 North America Molecular Diagnostics Market: SWOT Analysis Figure 4 Porter’s Analysis Figure 5 PEST Analysis Figure 6 North America Molecular Diagnostics Market Forecast by Technology, 2021-2031 (US$ million, AGR %) Figure 7 North America Molecular Diagnostics Market Share Forecast by Technology, 2021, 2026, 2031 (%) Figure 8 North America Molecular Diagnostics Market for Polymerase Chain Reaction Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 9 North America PCR Market for Sub-Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 10 North America Molecular Diagnostics Market for Polymerase Chain Reaction Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 11 North America Molecular Diagnostics Market for Polymerase Chain Reaction Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 12 North America Molecular Diagnostics Market for Polymerase Chain Reaction Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 13 North America Molecular Diagnostics Market for Polymerase Chain Reaction Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 14 North America Molecular Diagnostics Market for In Situ Hybridization Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 15 North America Molecular Diagnostics Market for In Situ Hybridization Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 16 North America Molecular Diagnostics Market for In Situ Hybridization Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 17 North America Molecular Diagnostics Market for In Situ Hybridization Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 18 North America Molecular Diagnostics Market for In Situ Hybridization Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 19 North America Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 20 North America Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 21 North America Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 22 North America Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 23 North America Molecular Diagnostics Market for Isothermal Nucleic Acid Amplification Technology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 24 North America Molecular Diagnostics Market for Chips and Microarrays Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 25 North America Molecular Diagnostics Market for Chips and Microarrays Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 26 North America Molecular Diagnostics Market for Chips and Microarrays Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 27 North America Molecular Diagnostics Market for Chips and Microarrays Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 28 North America Molecular Diagnostics Market for Chips and Microarrays Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 29 North America Molecular Diagnostics Market for Mass Spectrometry Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 30 North America Molecular Diagnostics Market for Mass Spectrometry Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 31 North America Molecular Diagnostics Market for Mass Spectrometry Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 32 North America Molecular Diagnostics Market for Mass Spectrometry Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 33 North America Molecular Diagnostics Market for Mass Spectrometry Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 34 North America Molecular Diagnostics Market for Sequencing Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 35 North America Molecular Diagnostics Market for Sequencing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 36 North America Molecular Diagnostics Market for Sequencing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 37 North America Molecular Diagnostics Market for Sequencing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 38 North America Molecular Diagnostics Market for Sequencing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 39 North America Molecular Diagnostics Market for Transcription Mediated Amplification Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 40 North America Molecular Diagnostics Market for Transcription Mediated Amplification Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 41 North America Molecular Diagnostics Market for Transcription Mediated Amplification Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 42 North America Molecular Diagnostics Market for Transcription Mediated Amplification Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 43 North America Molecular Diagnostics Market for Transcription Mediated Amplification Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 44 North America Molecular Diagnostics Market for Others Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 45 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 46 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 47 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 48 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 49 North America Molecular Diagnostics Market Forecast by Application, 2021-2031 (US$ million, AGR %) Figure 50 North America Molecular Diagnostics Market Share Forecast by Application, 2021, 2026, 2031 (%) Figure 51 North America Molecular Diagnostics Market for Oncology Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 52 North America Oncology Market for Sub-Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 53 North America Molecular Diagnostics Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 54 North America Molecular Diagnostics Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 55 North America Molecular Diagnostics Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 56 North America Molecular Diagnostics Market for Oncology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 57 North America Molecular Diagnostics Market for Pharmacogenomics Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 58 North America Molecular Diagnostics Market for Pharmacogenomics Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 59 North America Molecular Diagnostics Market for Pharmacogenomics Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 60 North America Molecular Diagnostics Market for Pharmacogenomics Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 61 North America Molecular Diagnostics Market for Pharmacogenomics Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 62 North America Molecular Diagnostics Market for Infectious Diseases Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 63 North America Infectious Diseases Market for Sub-Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 64 North America Molecular Diagnostics Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 65 North America Molecular Diagnostics Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 66 North America Molecular Diagnostics Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 67 North America Molecular Diagnostics Market for Infectious Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 68 North America Molecular Diagnostics Market for Genetic Testing Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 69 North America Genetic Testing Market for Sub-Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 70 North America Molecular Diagnostics Market for Genetic Testing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 71 North America Molecular Diagnostics Market for Genetic Testing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 72 North America Molecular Diagnostics Market for Genetic Testing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 73 North America Molecular Diagnostics Market for Genetic Testing Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 74 North America Molecular Diagnostics Market for Neurological Disease Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 75 North America Molecular Diagnostics Market for Neurological Disease Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 76 North America Molecular Diagnostics Market for Neurological Disease Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 77 North America Molecular Diagnostics Market for Neurological Disease Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 78 North America Molecular Diagnostics Market for Neurological Disease Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 79 North America Molecular Diagnostics Market for Cardiovascular Diseases Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 80 North America Molecular Diagnostics Market for Cardiovascular Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 81 North America Molecular Diagnostics Market for Cardiovascular Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 82 North America Molecular Diagnostics Market for Cardiovascular Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 83 North America Molecular Diagnostics Market for Cardiovascular Diseases Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 84 North America Molecular Diagnostics Market for Microbiology Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 85 North America Molecular Diagnostics Market for Microbiology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 86 North America Molecular Diagnostics Market for Microbiology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 87 North America Molecular Diagnostics Market for Microbiology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 88 North America Molecular Diagnostics Market for Microbiology Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 89 North America Molecular Diagnostics Market for Others Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 90 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 91 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 92 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 93 North America Molecular Diagnostics Market for Others Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 94 North America Molecular Diagnostics Market Forecast by Product, 2021-2031 (US$ million, AGR %) Figure 95 North America Molecular Diagnostics Market Share Forecast by Product, 2021, 2026, 2031 (%) Figure 96 North America Molecular Diagnostics Market for Instruments Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 97 North America Molecular Diagnostics Market for Instruments Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 98 North America Molecular Diagnostics Market for Instruments Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 99 North America Molecular Diagnostics Market for Instruments Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 100 North America Molecular Diagnostics Market for Instruments Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 101 North America Molecular Diagnostics Market for Reagents Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 102 North America Molecular Diagnostics Market for Reagents Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 103 North America Molecular Diagnostics Market for Reagents Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 104 North America Molecular Diagnostics Market for Reagents Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 105 North America Molecular Diagnostics Market for Reagents Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 106 North America Molecular Diagnostics Market Forecast by Test Location, 2021-2031 (US$ million, AGR %) Figure 107 North America Molecular Diagnostics Market Share Forecast by Test Location, 2021, 2026, 2031 (%) Figure 108 North America Molecular Diagnostics Market for Point-of-Care Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 109 North America Molecular Diagnostics Market for Point-of-Care Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 110 North America Molecular Diagnostics Market for Point-of-Care Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 111 North America Molecular Diagnostics Market for Point-of-Care Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 112 North America Molecular Diagnostics Market for Point-of-Care Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 113 North America Molecular Diagnostics Market for Over the Counter Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 114 North America Molecular Diagnostics Market for Over the Counter Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 115 North America Molecular Diagnostics Market for Over the Counter Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 116 North America Molecular Diagnostics Market for Over the Counter Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 117 North America Molecular Diagnostics Market for Over the Counter Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 118 North America Molecular Diagnostics Market for Central Laboratories Segment: Revenue Forecast 2021-2031 (US$ million, AGR%) Figure 119 North America Molecular Diagnostics Market for Central Laboratories Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 120 North America Molecular Diagnostics Market for Central Laboratories Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 121 North America Molecular Diagnostics Market for Central Laboratories Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 122 North America Molecular Diagnostics Market for Central Laboratories Segment, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 123 North America Molecular Diagnostics Market Forecast by Country 2021-2031 (US$ million) Figure 124 North America Molecular Diagnostics Market Share Forecast by Country 2021, 2026, 2031 (%) Figure 125 U.S. Molecular Diagnostics Market Forecast by Technology, 2021-2031 (US$ million, AGR%) Figure 126 U.S. Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 127 U.S. Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 128 U.S. Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 129 U.S. Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 130 U.S. Molecular Diagnostics Market Forecast by Application, 2021-2031 (US$ million, AGR%) Figure 131 U.S. Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 132 U.S. Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 133 U.S. Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 134 U.S. Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 135 U.S. Molecular Diagnostics Market Forecast by Product, 2021-2031 (US$ million, AGR%) Figure 136 U.S. Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 137 U.S. Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 138 U.S. Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 139 U.S. Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 140 U.S. Molecular Diagnostics Market Forecast by Test Location, 2021-2031 (US$ million, AGR%) Figure 141 U.S. Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 142 U.S. Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 143 U.S. Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 144 U.S. Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 145 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR %) Figure 146 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 147 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 148 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 149 U.S. Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 150 Canada Molecular Diagnostics Market Forecast by Technology, 2021-2031 (US$ million, AGR%) Figure 151 Canada Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 152 Canada Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 153 Canada Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 154 Canada Molecular Diagnostics Market by Technology, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 155 Canada Molecular Diagnostics Market Forecast by Application, 2021-2031 (US$ million, AGR%) Figure 156 Canada Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 157 Canada Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 158 Canada Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 159 Canada Molecular Diagnostics Market by Application, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 160 Canada Molecular Diagnostics Market Forecast by Product, 2021-2031 (US$ million, AGR%) Figure 161 Canada Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 162 Canada Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 163 Canada Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 164 Canada Molecular Diagnostics Market by Product, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 165 Canada Molecular Diagnostics Market Forecast by Test Location, 2021-2031 (US$ million, AGR%) Figure 166 Canada Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 167 Canada Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 168 Canada Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 169 Canada Molecular Diagnostics Market by Test Location, Revenue Forecast 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 170 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR %) Figure 171 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “V” Shaped Recovery Figure 172 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “U” Shaped Recovery Figure 173 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “W” Shaped Recovery Figure 174 Canada Molecular Diagnostics Market Forecast, 2021-2031 (US$ million, AGR%): “L” Shaped Recovery Figure 175 Roche Diagnostics: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 176 Roche Diagnostics: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 177 Roche Diagnostics: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 178 Roche Diagnostics: Net Income, 2015-2019 (US$ million, AGR%) Figure 179 Roche Diagnostics: EBDITA, 2015-2019 (US$ million, AGR%) Figure 180 Abbott: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 181 Abbott: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 182 Abbott: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 183 Abbott: Net Income, 2015-2019 (US$ million, AGR%) Figure 184 Abbott: EBDITA, 2015-2019 (US$ million, AGR%) Figure 185 Becton, Dickinson and Company: Net Revenue, 2015-2020 (US$ million, AGR%) Figure 186 Becton, Dickinson and Company: R&D Expenses, 2015-2020 (US$ million, AGR%) Figure 187 Becton, Dickinson and Company: Gross Profit, 2015-2020 (US$ million, AGR%) Figure 188 Becton, Dickinson and Company: Net Income, 2015-2020 (US$ million, AGR%) Figure 189 Becton, Dickinson and Company: EBDITA, 2015-2020 (US$ million, AGR%) Figure 190 bioMérieux SA: Net Revenue, 2016-2019 (US$ million, AGR%) Figure 191 bioMérieux SA: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 192 bioMérieux SA: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 193 bioMérieux SA: Net Income, 2016-2019 (US$ million, AGR%) Figure 194 bioMérieux SA: EBDITA, 2015-2019 (US$ million, AGR%) Figure 195 Bio-Rad Laboratories, Inc.: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 196 Bio-Rad Laboratories, Inc.: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 197 Bio-Rad Laboratories, Inc.: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 198 Bio-Rad Laboratories, Inc.: Net Income, 2015-2019 (US$ million, AGR%) Figure 199 Bio-Rad Laboratories, Inc.: EBDITA, 2015-2019 (US$ million, AGR%) Figure 200 Dako (Agilent Technologies): Net Revenue, 2015-2020 (US$ million, AGR%) Figure 201 Dako (Agilent Technologies): R&D Expenses, 2015-2020 (US$ million, AGR%) Figure 202 Dako (Agilent Technologies): Gross Profit, 2015-2020 (US$ million, AGR%) Figure 203 Dako (Agilent Technologies): Net Income, 2015-2020 (US$ million, AGR%) Figure 204 Dako (Agilent Technologies): EBDITA, 2015-2020 (US$ million, AGR%) Figure 205 Danaher: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 206 Danaher: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 207 Danaher: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 208 Danaher: Net Income, 2015-2019 (US$ million, AGR%) Figure 209 Danaher: EBDITA, 2015-2019 (US$ million, AGR%) Figure 210 Genomic Health (Exact Sciences Corporation): Net Revenue, 2015-2019 (US$ million, AGR%) Figure 211 Genomic Health (Exact Sciences Corporation): R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 212 Genomic Health (Exact Sciences Corporation): Gross Profit, 2015-2019 (US$ million, AGR%) Figure 213 Genomic Health (Exact Sciences Corporation): Net Income, 2015-2019 (US$ million, AGR%) Figure 214 Genomic Health (Exact Sciences Corporation): EBDITA, 2015-2019 (US$ million, AGR%) Figure 215 Hologic, Inc.: Net Revenue, 2015-2020 (US$ million, AGR%) Figure 216 Hologic, Inc.: R&D Expenses, 2015-2020 (US$ million, AGR%) Figure 217 Hologic, Inc.: Gross Profit, 2015-2020 (US$ million, AGR%) Figure 218 Hologic, Inc.: Net Income, 2015-2020 (US$ million, AGR%) Figure 219 Hologic, Inc.: EBDITA, 2015-2020 (US$ million, AGR%) Figure 220 Illumina, Inc.: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 221 Illumina, Inc.: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 222 Illumina, Inc.: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 223 Illumina, Inc.: Net Income, 2015-2019 (US$ million, AGR%) Figure 224 Illumina, Inc.: EBDITA, 2015-2019 (US$ million, AGR%) Figure 225 HTG Molecular Diagnostics, Inc.: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 226 HTG Molecular Diagnostics, Inc.: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 227 HTG Molecular Diagnostics, Inc.: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 228 HTG Molecular Diagnostics, Inc.: Net Income, 2015-2019 (US$ million, AGR%) Figure 229 HTG Molecular Diagnostics, Inc.: EBDITA, 2015-2019 (US$ million, AGR%) Figure 230 Grifols, S.A.: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 231 Grifols, S.A.: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 232 Grifols, S.A.: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 233 Grifols, S.A.: Net Income, 2015-2019 (US$ million, AGR%) Figure 234 Grifols, S.A.: EBDITA, 2015-2019 (US$ million, AGR%) Figure 235 QIAGEN: Net Revenue, 2015-2019 (US$ million, AGR%) Figure 236 QIAGEN: R&D Expenses, 2015-2019 (US$ million, AGR%) Figure 237 QIAGEN: Gross Profit, 2015-2019 (US$ million, AGR%) Figure 238 QIAGEN: Net Income, 2015-2019 (US$ million, AGR%) Figure 239 QIAGEN: EBDITA, 2015-2019 (US$ million, AGR%) Figure 240 Siemens Healthcare GmbH: Net Revenue, 2015-2020 (US$ million, AGR%) Figure 241 Siemens Healthcare GmbH: R&D Expenses, 2015-2020 (US$ million, AGR%) Figure 242 Siemens Healthcare GmbH: Gross Profit, 2015-2020 (US$ million, AGR%) Figure 243 Siemens Healthcare GmbH: Net Income, 2015-2020 (US$ million, AGR%) Figure 244 Siemens Healthcare GmbH: EBDITA, 2015-2020 (US$ million, AGR%) Figure 245 Sysmex Corporation: Net Revenue, 2016-2020 (US$ million, AGR%) Figure 246 Sysmex Corporation: Gross Profit, 2016-2020 (US$ million, AGR%) Figure 247 Sysmex Corporation: Net Income, 2016-2020 (US$ million, AGR%) Figure 248 Sysmex Corporation: EBDITA, 2016-2020 (US$ million, AGR%)
Companies Profiled in the Report Abbott Becton, Dickinson, and Company Bio-Rad Laboratories, Inc. bioMérieux SA Dako (Agilent Technologies) Danaher FOUNDATION MEDICINE, INC. Genomic Health (Exact Sciences Corporation) Grifols, S.A. Hologic, Inc. HTG Molecular Diagnostics, Inc. Illumina, Inc. QIAGEN Roche Diagnostics Siemens Healthcare GmbH Sysmex Corporation
List of Other Companies AdvanDx Alere Autogenomics, Inc. AvariaDx Bina Technologies, Inc. Bio-Reference Laboratories BIOBASE Biocartis BioFire Diagnostics bioTheranostics CareFusion Corporation Celera Diagnostics DiaGenic DiagnoCure Dutalys DxS Gen-Probe Great Basin Scientific, Inc. Infectio Diagnstic, Inc. Intelligent Medical Devices, Inc. MDx Health Meridian Bioscience, Inc. Myriad Genetic Laboratories, Inc. Olerup SSP AB One Lambda OPKO Quest Diagnostics, Inc. Quidel Corporation Signature Diagnostics AG Ventana Medical Systems, Inc.
List of Organizations American Medical Association FDA's Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) National Institute for Health and Clinical Excellence (NICE) Rashtriya Swasthya Bima Yojana (RSBY) - (Indian National Health Insurance Programme) Rospotrebnadzor Federal Monitoring Agency Seguro Popular (Mexican National Health Insurance Programme) United Nations Population Division US Centers for Disease Control and Prevention (CDC) US Centers for Medicare and Medicaid Services (CMS) US Congressional Research Service (CRS) US Food and Drug Administration (FDA) US National Healthcare Safety Network (NHSN) USPS (United States Postal Service) World Health Organisation (WHO)
Download sample pages
Complete the form below to download your free sample pages for North American Molecular Diagnostics (MDx) Market Report 2021-2031
The government support to promote the adoption of these diagnostic tests, technological advancement, increased inclination for home healthcare, and rise...
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
